TAK 041

Drug Profile

TAK 041

Alternative Names: TAK-041

Latest Information Update: 10 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Takeda
  • Class
  • Mechanism of Action GPR139 protein agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cognition disorders

Most Recent Events

  • 27 Oct 2017 Takeda plans a phase II trial for Schizophrenia (Adjunctive therapy) in November 2017 (NCT03319953)
  • 01 Jan 2017 Phase-I clinical trials in Cognition disorders (In volunteers) in United Kingdom (PO) (NCT02959892)
  • 07 Nov 2016 Takeda plans a phase I trial in Healthy volunteers in United Kingdom (PO, Suspension) (NCT02959892)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top